A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma

A Phase Ib, open-label, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous glofitamab following obinutuzumab pretreatment in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

This study runs in
N/A
Study Identifier:

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other studies on ForPatients in related disease areas.

      Clinical Research Explained

      Information about what clinical studies and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now